| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/11/1996 | CA2193809A1 Modified g-protein coupled receptors |
| 01/11/1996 | CA2193802A1 Aav capsid vehicles for molecular transfer |
| 01/11/1996 | CA2192957A1 Semenogelin-derived oligopeptides cleavable by prostate specific antigen |
| 01/11/1996 | CA2190977A1 Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
| 01/11/1996 | CA2190883A1 Adenovirus including a gene coding for a superoxide dismutase |
| 01/11/1996 | CA2190756A1 Endothelin antagonists ii |
| 01/11/1996 | CA2190642A1 Agents affecting thrombosis and hemostasis |
| 01/10/1996 | EP0691406A1 Process for the preparation of superoxide dismutase by recombinant DNA-technology |
| 01/10/1996 | EP0691403A1 Family of primate IP-3-like hemapoietic growth factors |
| 01/10/1996 | EP0691402A2 Modified satellite-RNA's and satellite-viruses as support for adapted ribozymes |
| 01/10/1996 | EP0691401A1 Human manganese superoxide dismutase analogs, pharmaceutical compositions containing them, and use thereof |
| 01/10/1996 | EP0691350A2 uPA binding sites on domain 2+3 on uPAR and antibodies reactive therewith |
| 01/10/1996 | EP0691349A2 Dimeric bone morphogenic proteins and fragments and analogs thereof and pharmaceutical compositions comprising them |
| 01/10/1996 | EP0691345A2 HIV protease inhibitor combinations |
| 01/10/1996 | EP0691344A1 Purification of trehalose |
| 01/10/1996 | EP0691079A2 Enteral composition for diabetic patients |
| 01/10/1996 | EP0690991A1 Novel anticoagulant cofactor activity |
| 01/10/1996 | EP0690990A1 Parvovirus receptors and methods of use |
| 01/10/1996 | EP0690918A1 Protein tyrosine phosphatase ptp-s31 |
| 01/10/1996 | EP0690915A1 Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof |
| 01/10/1996 | EP0690914A1 Allergenic protein and peptides from house dust mite and uses therefor |
| 01/10/1996 | EP0690876A1 Protein kinases |
| 01/10/1996 | EP0690872A1 Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
| 01/10/1996 | EP0690871A1 Growth differentiation factor-5 |
| 01/10/1996 | EP0690841A1 Synthetic matrix metalloprotease inhibitors and uses thereof |
| 01/10/1996 | EP0690725A1 Methods for inhibiting hiv associated disease using monoclonal antibodies directed against anti-self cytotoxic t-cells |
| 01/10/1996 | EP0690722A1 Composition and method for reducing toxicity of biologically-active factors |
| 01/10/1996 | EP0690721A1 Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
| 01/10/1996 | EP0690720A1 Therapeutic uses of bactericidal/permeability increasing protein products |
| 01/10/1996 | EP0690717A1 Use of oligosaccharide glycosides as inhibitors of bacterial adherence |
| 01/10/1996 | EP0690709A1 Pharmaceutical composition for the treatment of certain viruses and autoimmune diseases and the procedure of its preparation |
| 01/10/1996 | EP0690675A1 Nucleic acid coding for a tumor rejection antigen precursor |
| 01/10/1996 | EP0690673A1 Systemic gene treatment of connective tissue diseases |
| 01/10/1996 | EP0605578B1 Pressurised aerosol compositions |
| 01/10/1996 | EP0599850B1 Composition and method for treating cystic fibrosis |
| 01/10/1996 | EP0563062B1 Hexapeptides deriving from aglucoteicoplanin and a process for preparing them |
| 01/10/1996 | EP0558529B1 Pharmaceutical preparation for the treatment of prolonged coagulation time |
| 01/10/1996 | EP0556241B1 Mycobacterium vaccae in the treatment of uveitis |
| 01/10/1996 | EP0493433B1 Method for improving human monoclonal antibody production and cells used therein |
| 01/10/1996 | EP0487611B1 Herpes simplex virus type 1 mutant |
| 01/10/1996 | CN1114836A Displacement chromatography process and purified hemoglobin product |
| 01/10/1996 | CN1114588A Formulations for orally administered pharmaceutical agents |
| 01/09/1996 | US5482947 Retroviral protease inhibitors |
| 01/09/1996 | US5482931 Stabilized pharmaceutical peptide compositions |
| 01/09/1996 | US5482930 Anti-inflammatory composition and method with des-Tyr dynorphin and analogues |
| 01/09/1996 | US5482929 Aluminum salt of cyclodextrin sulfate |
| 01/09/1996 | US5482928 Biocidal proteins |
| 01/09/1996 | US5482927 Injectable particles with active protein |
| 01/09/1996 | US5482926 Growth factor IGF-Il |
| 01/09/1996 | US5482925 Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents |
| 01/09/1996 | US5482924 Proteinaceous compositions having an activity on erythropoiesis |
| 01/09/1996 | US5482923 Heparin neutralization with platelet factor 4 fragments |
| 01/09/1996 | US5482853 Nuclear sequence for cellular genomes |
| 01/09/1996 | US5482838 Down-regulation of plasminogen activator inhibitor and beta-amyloid precursor protein |
| 01/09/1996 | US5482713 Equine herpesvirus recombinant poxvirus vaccine |
| 01/09/1996 | US5482709 Eimeria antigenic composition which elicits antibodies against avian coccidiosis |
| 01/09/1996 | US5482706 A physiologically active peptide or protein and a cytidine nucleotide |
| 01/09/1996 | CA2153208A1 Upa binding sites on domain 2+3 on upar and antibodies reactive therewith |
| 01/09/1996 | CA1337898C High integrity liposomes and method of preparation and use |
| 01/06/1996 | CA2153270A1 Hiv protease inhibitor combinations |
| 01/05/1996 | CA2153109A1 Synthetic peptide derivatives and the salts thereof |
| 01/04/1996 | WO1996000297A1 INTERLEUKIN-1 β CONVERTING ENZYME LIKE APOPTOSIS PROTEASE-1 AND 2 |
| 01/04/1996 | WO1996000289A1 Protocadherin proteins and their uses |
| 01/04/1996 | WO1996000288A2 Class bi and ci scavenger receptors |
| 01/04/1996 | WO1996000287A1 Dna coding for caldecrin and process for producing caldecrin by using the dna |
| 01/04/1996 | WO1996000286A1 Antisense nucleic acid compound |
| 01/04/1996 | WO1996000242A1 Retinoic acid receptor epsilon |
| 01/04/1996 | WO1996000240A1 Novel protein and process for producing the same |
| 01/04/1996 | WO1996000238A1 T cell epitopes of rye grass pollen allergen |
| 01/04/1996 | WO1996000233A1 Escherichia coli o157:h7 epithelial adhesin |
| 01/04/1996 | WO1996000086A1 Therapeutic method and remedy for diabetes |
| 01/04/1996 | WO1996000084A1 Use of autoantibodies for tumor therapy and prophylaxis |
| 01/04/1996 | WO1996000082A1 Medical use of bromelain |
| 01/04/1996 | WO1996000081A1 Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
| 01/04/1996 | WO1996000080A1 Non-antigenic amine derived polymers and polymer conjugates |
| 01/04/1996 | WO1996000058A1 Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| 01/04/1996 | WO1996000007A1 Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| 01/04/1996 | WO1996000006A1 Inducible nitric oxide synthase gene for treatment of disease |
| 01/04/1996 | WO1995034649A3 Polycystic kidney disease 1 gene and uses thereof |
| 01/04/1996 | WO1995033464A3 Retroviral protease inhibitor combinations |
| 01/04/1996 | WO1995033049A3 Tbp2 fragments of the transferrine receptor of neisseria meningitidis |
| 01/04/1996 | WO1995031985A3 Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies |
| 01/04/1996 | WO1995030015A3 Isolated epstein-barr virus bzlf2 proteins that bind mhc class ii beta chains |
| 01/04/1996 | WO1995029193A3 Melanoma antigens |
| 01/04/1996 | WO1995025806A3 Packaging-deficient lentiviruses |
| 01/04/1996 | DE4423131A1 Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4 |
| 01/04/1996 | DE19511243A1 Neuer Wachstums-/Differenzierungsfaktor der TGF-beta-Familie New growth / differentiation factor of the TGF-beta family |
| 01/04/1996 | CA2193860A1 T cell epitopes of rye grass pollen allergen |
| 01/04/1996 | CA2193832A1 Class bi and ci scavenger receptors |
| 01/04/1996 | CA2193827A1 Inducible nitric oxide synthase gene for treatment of disease |
| 01/04/1996 | CA2193654A1 Medical use of bromelain |
| 01/04/1996 | CA2192821A1 Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
| 01/04/1996 | CA2191726A1 Non-antigenic amine derived polymers and polymer conjugates |
| 01/04/1996 | CA2170156A1 Protocadherin proteins and their uses |
| 01/04/1996 | CA2169953A1 Basic osteoblast growth factor ii (bogf-ii) and methods for producing it |
| 01/03/1996 | EP0690307A1 Method of determining the presence of an autoimmune antibody |
| 01/03/1996 | EP0690132A1 Anti-hiv monoclonal antibody |
| 01/03/1996 | EP0690129A1 Novel entities for cancer therapy |
| 01/03/1996 | EP0690127A1 Compositions and methods for stimulating megakaryocyte growth and differentiation |
| 01/03/1996 | EP0690126A1 Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |